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  1  Nonstandard abbreviations: ICMJE, International Committee of Medical Journal Editors; STARD, Standards for Reporting of Diagnostic 
Accuracy; cTnI, cardiac troponin I; PSA, prostate-speciﬁ  c antigen; fPSA, free PSA; tPSA, total PSA; %fPSA, percentage of fPSA.
EDITORIAL
                                                          An Appeal to Medical Journal Editors: The Need for a Full 
Description of Laboratory Methods and Specimen Handling in 
Clinical Study Reports                                                                             
  We, the editors of the laboratory medicine journals, 
urge our colleagues in the International Committee 
of Medical Journal Editors (ICMJE)  1   to adopt and 
enforce the following requirements for clinical stud-
ies that include laboratory testing for biomarkers, 
and to add these statements to the information for 
authors:     
  1.   For commercial diagnostic tests, authors must 
include the actual name and generation of assay, 
the manufacturer, and the instrument used for 
analyses.     
  2.   Authors must report performance characteris-
tics, such as the imprecision of the assay in the 
investigators  ’   laboratories, the assay  ’  s reportable 
range, and any reference (normal) range used in 
the study.     
  3.   Authors must clearly indicate the types of speci-
mens analyzed and the storage conditions for 
these specimens.     
  The rationale for these requirements is provided 
below. 
  Biochemical markers (here referred to as bio-
markers) are being used increasingly in the diagnosis, 
staging, and prognosis of various diseases, as well as 
in the monitoring of response and determination of 
compliance with prescribed treatment regimens. 
Although a biomarker initially is developed and 
approved by regulatory agencies for a particular clin-
ical use, other potential clinical applications of that 
biomarker usually evolve over time (e.g., cardiac tro-
ponin, B-type natriuretic peptide, C-reactive pro-
tein). These new potential applications often require 
the manufacturer to develop a more analytically sen-
sitive or speciﬁ  c assay to meet the new clinical needs. 
It is common to have multiple generations of assays 
for a particular biomarker in the marketplace con-
currently (cardiac troponin, thyroid-stimulating hor-
mone). With the recent wave of mergers and 
acquisitions in the in vitro diagnostics industry, a 
single manufacturer can have multiple platforms and 
may feel obligated to have a similar menu of testing 
on all of them. In many cases, the same reagents for 
a given biomarker measurement may end up being 
used on several instruments that yield different 
results. Standardization and harmonization studies 
are directed at addressing these concerns to assure 
that the same result can be obtained for a biomarker, 
regardless of the method used for its measurement; 
however, such efforts are difﬁ  cult, time-consuming, 
costly, and in some cases simply not feasible (e.g., 
measurement of ﬁ  brinogen by a functional assay). 
For many of the new biomarkers, standardization 
activities either are nonexistent or have been initiated 
but not ﬁ  nished. Therefore, it is crucial for authors 
of scientiﬁ  c reports to provide detailed information 
regarding the methods used in their studies for the 
measurement of biomarkers and for journal editors 
to demand such information so that the reader can 
interpret the ﬁ  ndings. 
  In 2003, a group of scientists and editors devel-
oped the Standards for Reporting of Diagnostic 
Accuracy (STARD) statement, which was published 
in several laboratory and medical journals [1]. These 
guidelines, meant to improve the reporting and qual-
ity of studies of diagnostic accuracy, were endorsed 
in 2006 by the ICMJE (http://www.icmje.com). The 
STARD statement contained a checklist of 15 impor-
tant items of information for authors to provide and 
for editors to require. Item no. 8 refers to the impor-
tance of describing in full the laboratory methods 
used and their performance characteristics. Similar 
recommendations were also made by REMARK for 
the reporting of tumor marker prognostic studies 
(item no. 5) [2]. Despite the obvious importance of 
the information recommended by these guidelines, 
however, progress in improving published reports on 
diagnostic accuracy has been modest [3]. Unfortu-
nately, it remains common for descriptions of labora-
tory methods to be either incomplete or absent in 
reports describing sophisticated clinical studies that 
are published in excellent medical journals. The lab-
oratory medicine journal editors would like to urge 
their medical journal editor colleagues to play a more 
active role in requiring a full description of laboratory 
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assays used in clinical reports, and we provide these 
editors with 2 examples to illustrate the importance 
of disclosing such information.   
  Example I 
  Cardiac troponins I (cTnI) and T (cTnT) have been 
recognized as the biomarkers of choice for the detec-
tion of myocardial injury and in the diagnosis 
of myocardial infarction and risk stratiﬁ  cation  of 
patients presenting with symptoms of acute coronary 
syndrome. Laboratory and clinical professional soci-
eties endorsed the use of the 99th-percentile value 
derived from a reference population as the clinical-
decision threshold [4, 5]. 
  At the present time, there are 23 cardiac troponin 
assays available (21 for cTnI, 2 for cTnT) from 14 
manufacturers [6]. Four of these assays are for research 
use only, but data about their clinical utility have 
already made their way into the literature. Depending 
on their analytical sensitivity and imprecision charac-
teristics, contemporary and high-sensitivity cardiac 
troponin assays are classiﬁ  ed into one of 4 categories 
[6]. Most cTnI assays use antibodies that are unique 
to the manufacturer and recognize different antigenic 
sites [7]. Therefore, different manufacturers  ’   assays 
measure different isoforms and/or fractions of the 
cTnI molecule [8]. As a result, the various cTnI assays 
yield different results for the same clinical sample; 
standardization efforts for cTnI assays have been ham-
pered by these difﬁ  culties. A single manufacturer may 
have multiple cTnI assays on several analyzers with 
different performance characteristics. For example, 
Siemens has 5 cTnI assays on 5 different analyzers 
that yield 99th-percentile values ranging from 40 to 
200 ng/L, despite the fact that they are all classiﬁ  ed 
as contemporary assays [6]. Beckman Coulter has 2 cTnI 
assays, a ﬁ  rst-generation assay and a third-generation high-
sensitivity assay, which have 99th percentiles of 40 
ng/L and 8.6 ng/L, respectively [6]. 
  It is impossible for the reader to fully appraise 
the content, value, impact, and generalizability of a 
clinical study that utilizes cardiac troponin without 
knowing the exact cardiac troponin assay used and 
its performance characteristics. It is equally impos-
sible for the researcher to perform a valid metaanal-
ysis study assessing the utility of cardiac troponin 
in a particular clinical scenario without knowing 
the assays used in each of the studies included in 
the metaanalysis. Such information ensures that 
only data from comparable troponin assays are 
pooled.     
  Example II 
  Although prostate-speciﬁ  c antigen (PSA) is used for 
the early detection of prostate cancer, its concentra-
tion is increased in patients with prostatitis and 
benign prostate hyperplasia. The measurement of 
free PSA (fPSA) and the determination of the ratio 
of fPSA to total PSA (tPSA), the so-called percent-
age of fPSA (%fPSA), helps to reduce the false-positive 
rate, thus avoiding unnecessary biopsy [9]. A variety 
of algorithms to improve prostate cancer risk predic-
tion by combining age, tPSA, %fPSA, direct rectal-
examination results, and/or prostate volume have 
been developed with data from different populations, 
by applying various tPSA intervals, and by using 
different manufacturers  ’   PSA assays [10]. 
  Although interassay variability among commer-
cially available methods for tPSA and fPSA has 
improved as a result of using WHO PSA reference 
materials and developing equimolar-response assays, 
harmonization among methods is poor, and the 
interchangeability of tPSA, fPSA, and %fPSA results 
obtained by various assays is inadequate [11]. As a 
result, the diagnostic accuracy of prostate cancer 
risk prediction using a particular risk algorithm 
depends on the tPSA and fPSA assays used [12]. In 
addition, not considering PSA between-method dif-
ferences [13] can lead to questionable conclusions 
regarding the performance of prediction tools of 
prostate cancer [14]. Therefore, it is imperative that 
the authors of such reports provide sufﬁ  cient infor-
mation regarding the methods used, to enable the 
reader to correctly evaluate the presented work and 
to be able to compare it to previously published 
studies. 
  Furthermore, every assay or analytical technique 
used in a study requires a specimen. Therefore, the 
type of specimen analyzed (e.g., serum vs plasma), 
type of blood-collection tube used (anticoagulant), 
storage conditions (refrigerated/frozen, temperature 
and duration of storage before analysis, freeze/thaw 
cycles), and analyte stability (especially for new bio-
markers) may turn out to be important to the inter-
pretation of results or the ability of others to 
reproduce the study. The reference range and the 
analytical reproducibility (imprecision) may also be 
assay-to-assay and site-to-site dependent, and there-
fore should be reported. 
  Prior to the electronic-publishing era, authors 
had to communicate their data and thoughts within 
strict word-limit constraints, with no other option 
for communicating additional information. There-
fore, it is understandable that they kept their descrip-
tions of laboratory methods to a minimum and 
elaborated on their ﬁ   ndings. With the increasing 
availability of electronic supplements, however, 
authors have a mechanism to provide all needed 
information regarding the laboratory methods used 
in a study, thus enabling readers to fully evaluate the 
work. We sincerely hope that medical journal editors 
see the value of this argument and insist on having 
this information available to the reader. This rela-
tively minor step will go a long way toward improv-
ing the quality of reporting the use of biomarkers in 
diagnostic studies.   Appeal to Medical Journal Editors    91
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